138P Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial

Until recently, neoadjuvant therapy for HCC has been limited by a lack of effective approaches. Prior studies have shown that patients (pts) achieving major pathological response (MPR) with neoadjuvant therapy have improved recurrence-free survival (RFS) in early-stage hepatocellular carcinoma (HCC). This prospective study aimed to explore the efficacy and safety of TACE combined with lenvatinib and tislelizumab in high-risk resectable HCC pts.